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Introduction
Cisplatin is one of the most efficient solid-tumour
chemotherapy agents. However, toxicity is a serious
problem. A detailed review about modulators of cispla-
tin-induced side-effects was published recently [1]. In
the kidney, cisplatin is freely filtered as well as secreted
by tubular cells. Acute toxicity is mainly reflected by
proximal tubular dysfunction [2,3]. Acute cisplatin
nephrotoxicity is dose-dependent, but can be largely
prevented by adequate hydration of the patients. In
contrast to the good characterization of acute nephro-
toxicity, controversy exists regarding deleterious long-
term renal side-effects of this agent. There is little
doubt that repeated applications of cisplatin may lead
to chronic renal impairment. However, according to
the literature, kidney function seems to stabilize on a
lower functional level with no or very little further
deterioration after completion of chemotherapy [4-6].
In this report we present two rare cases of chronic
renal failure with relentless deterioration of renal func-
tion even many years after completion of cisplatin
therapy.
Case reports
Patient 1
A white male, 24 years of age, was referred to the
Division of Nephrology of the Inselspital Bern for
evaluation of deteriorating kidney function.
In 1989 a diagnosis was made of embryonal teratoma
in the right testicle with metastasis to many organs,
including retroperitoneal lymph nodes and the right
kidney. During the period of November 1989 until
March 1990 six courses of chemotherapy were given,
consisting of cisplatin (1400mg, equal to 650 mg/m2
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of body surface), etoposid (7 g) and ifosfamide (72 g,
in daily dosages of 1.1 g/m2 of body surface). Prior to
this treatment, renal function was slightly impaired
with a creatinine level of 120 umol/1 (Figure 1). Kidney
function normalized soon after initiation of chemother-
apy, probably because of the cytotoxic effect on tumour
deposits in the right kidney and retroperitoneal lymph-
atics. However, soon after completion of the six courses
of cisplatin, relentless deterioration of the patient's
renal function was observed (Figure 1).
On admission to the renal clinic in July 1994,
the patient was free of tumour. He was obese
(132 kg, 182 cm) with a normal blood pressure of
130/85 mmHg. Kidney function was impaired as
reflected by a creatinine concentration of 180 umol/1.
Urine analysis showed microhaematuria and pro-
teinuria of 1.5 g/24 h. Computed tomography of
the abdomen demonstrated normal kidneys without
obvious parenchymal damage. A kidney biopsy was
performed. Renal histology (40 glomeruli) was charac-
terized predominantly by tubular alterations, such as
atypically enlarged tubular cells with great variation
in size and shape of the nucleus, mostly with visible
nucleoli. In the interstitium, a slight infiltration of
mononuclear leukocytes was seen (Figure 2). Electron-
microscopy disclosed no major glomerular abnormalit-
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Fig. 1. Serum creatinine concentrations in patient 1 from 1989
(beginning of cisplatin treatment) until 1994, i.e. 4 years after
completion of chemotherapy. Abbreviations: cis, cisplatin; eto,
etoposide; ifo, ifosfamide.
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Fig. 2. Histology from patient 1. The glomerulus, with the exception
of prominent juxtaglomerular cells, is normal. The proximal tubular
cells are variable in size. The tubular cell nuclei are slightly poly-
morphic. H & E, 175 x .
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Fig. 3. Serum creatinine concentrations in patient 2 prior to chemo-
therapy in 1983 until 9 years after completion of cisplatin treatment
in 1994. A, Cytotoxic therapy with vinblastin, bleomycin, and
cisplatin; B, cytotoxic therapy with alternating vinblastin, bleomycin,
cisplatin and cosmegen, etoposide, ifosfamide respectively.
ies. The nuclear changes of tubular epithelia were also
evident, in addition to minor cytoplasmic changes.
Patient 2
In this 51-year-old white male, seminoma of the right
testicle with secondaries in retroperitoneal and hilar
lymph nodes of the lung was diagnosed in 1981.
In January 1982, the right testicle was removed. A
dose of 40 Gy each was applied to the para-aortic and
iliac region, as well as to the supraclavicular areas and
mediastinum. Because of tumour recurrence with meta-
stases in both lungs, three courses of chemotherapy
consisting of vinblastin, bleomycin, and cisplatin were
given from June to August 1983. The patient responded
well to this treatment; however, the creatinine level
increased from 90 to 158umol/l (Figure 3); later, it
decreased spontaneously to 100 umol/1. Because of
reappearance of lung metastases, several courses of
chemotherapy composed of vinblastin, bleomycin, and
cisplatin alternating with cosmegen, etoposide and ifos-
famide (15 g in daily dosages of 1.4 g/m2 of body
surface) were given in the period of March to July
1985. After completion of this chemotherapy, the
patient's chronic renal failure progressed relentlessly.
The patient remained in complete and sustained remis-
sion from his tumour; the total amount of cisplatin
was in the order of 1150mg (650mg/m2 of body
surface).
This patient was finally referred to the Division of
Nephrology of the Inselspital Bern because of his
impaired renal function, in August 1994. On admission
he was in good general condition with a normal body
weight of 65.5 kg in relation to his height. Physical
examination was entirely normal with a blood pressure
of 120/80 mmHg. However, the patient had chronic
renal failure with a urea of 20.3 mmol/1 and a creatinine
of 359 umol/1. Analysis of a 24-h urine collection
showed a mild proteinuria of 480 mg and a severely
reduced creatinine clearance of 25 ml/min (Figure 3).
On ultrasonic examination, the kidneys were moder-
ately reduced in size. There were no signs of a obstruc-
tion in the urinary tract. Urine analysis showed few
granular casts, mild haematuria and proteinuria. The
kidney biopsy (50 glomeruli) showed non-specific
advanced glomerular and tubular scarring and inter-
stitial infiltration predominantly by mononuclear leu-
kocytes as well as focal areas of tubular hyperplasia.
Discussion
We describe two patients with normal serum creatinine
levels prior to (patient 2) or shortly after (patient 1)
initiation of cisplatin therapy, in whom chronic renal
failure developed and progressed during the observa-
tion periods of 5 and 11 years respectively. With the
exception of ifosfamide there were no other drugs with
known renal toxicity. Side-effects of ifosfamide (mainly
tubular toxicity) have been discussed and compared to
those of cisplatin elsewhere [3,7]. According to Skinner
et al. the combination of ifosfamide with other poten-
tial nephrotoxic drugs such as aminoglycosides, acyclo-
vir, or cisplatin may increase the risk of nephrotoxic
side-effects [8]. Brandis estimated the overall incidence
of renal tubular dysfunction in patients treated with
ifosfamide to vary between 10 and 20%, with only
1-3% of cases showing severe clinical symptoms [3].
Chronic renal failure due to ifosfamide is extremly rare
and occurred in patients treated with very high doses
(daily dosages >5 g/m2) [9]. However, our patients
were well below this limit.
To one patient radiotherapy to the para-aortic region
was given (case 2). However, the kidneys were appro-
priately shielded and the dose affecting the kidneys
was well below the accepted tolerance level of 20
Gy[10].
Therefore the progressive renal failure in both of
our cases is most probably due to the use of cisplatin,
possibly potentiated by ifosfamide. This is a very rare
occurrence. In the literature we have found reports of
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Table 1. Mean cumulative cisplatin doses and percentage reduction of GFR in studies with observation periods of at least 12 months
Source of
data
Dentino15
Fjeldborg4
Groth16
Hansen5
Macleod17
Hamilton18
Daugaard19
Daugaard19
Osanto20
Brillet11
Uozumi21
Year
1978
1986
1986
1988
1988
1989
1990
1990
1992
1993
1993
Number
of patients
15
22
25
34
22
22
41
30
43
1
17
Mean
age
22
23
24
34
31
28
uk
uk
30
31
52
Cumulative
cisplatin dose.
300-500*
452**
60**
583*
670*
300-
400*
600*
483*
540*'
500*
698***
Mean %
reduction
of GFR
44
13
29
10
23
22
12
36
15
D
4
Mean observation
period (months)
(r = Range)
24
16-52 (r)
12
65
22
30
24
24
49
24
22
* Range of dose (mg/m2 of body surface).
** Mean dose (mg/m2 of body surface).
*** Total dose (mg).
D, Haemodialysis required within 12 months,
uk, Unknown.
only three patients comparable to our two patients
with chronic and progressive renal failure [11,12].
Brillet et al. reported four cases of end-stage renal
failure due to cisplatin administration [11]. In two
cases there was significant dehydration during cisplatin
treatment, and one patient had one kidney removed a
month prior to cisplatin exposure. In these three
patients, dialysis was required within 15 days follow-
ing chemotherapy. The fourth patient was treated
with 5-fluorouracil, VP16, mitomycin and cisplatin
(540 mg). The creatinine concentration rose from
60 umol/1 to 340 umol/1. The patient developed end-
stage kidney disease within 1 year after termination of
cisplatin therapy. Of these four patients, only the last
one is really comparable to our two patients and is
shown in Table 1, where only patients with an observa-
tion period of 12 months or longer are represented.
Rebmann et al. investigated the kidney function in
38 patients with testicular tumours [12]. The patients
received one course of chemotherapy containing vin-
blastin, cyclophosphamide, actinomycin D, bleomycin,
and cisplatin 120 mg/m2, followed by an unstated
number of courses of vinblastin, adriblastin, leukeran,
actinomycin, and cisplatin 50 mg/m2. There was either
transient or permanent but stable deterioration in
kidney function in 31 patients. Two of 31 developed
chronic renal failure. In one patient the creatinine level
remained stable at a value of 400 umol/1, the other
patient developed end-stage renal disease. Both histor-
ies are very similar to that of our two patients, although
Rebmann et al. did not state the observation period in
his paper, and therefore these patients are not shown
in Table 1.
Several investigators described a decrease in renal
function during the period of cisplatin administration
(Table 1). In these studies renal function seemed to
stabilize with no [4,15,18-20] or little [5,17] further
deterioration after cessation of cisplatin exposure. Only
one patient was described with a marked decline in
renal function in the study performed by Macleod
[17]. In this patient the observation period was
restricted to 12 months. Thus it remains unclear
whether or not the renal function stabilized later on.
Groth et al. observed a mean decrease in GFR of
about 29% during the first 12 months after cessation
of therapy in 25 patients [16]. The decline in GFR
showed an exponential pattern within the observation
period, suggesting no further decline after 12 months.
Unfortunately Uozumi et al. did not indicate the exact
time point of the assessment of the renal function in
relation to the end of cytostatic therapy [21]. Therefore
one cannot establish whether or not the GFR declined
later on.
The mechanisms which give rise to the chronic
nephropathy are conjectural. Cisplatin is known to be
concentrated in the renal cortex, where it can be
detected up to 4 weeks after cessation of treatment
[13]. It may lead to direct and indirect toxic injuries.
It has an effect on renal tubules, in analogy to the
toxic effects of other heavy metals [14]. Cisplatin
further causes a substantial decrease in median glomer-
ular filtration rate and effective renal plasma flow,
perhaps via an indirect vasomotoric effect that results
in increased vascular resistance [4,14]. The combined
vascular and tubular alterations may result in paren-
chymal atrophy, interstitial inflammation, and prob-
ably irreversible interstitial fibrosis. The reasons of the
progressive deterioration and the self-perpetuation of
the renal damage are unknown.
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